FibroBiologics Stock (NASDAQ:FBLG)
Previous Close
$2.10
52W Range
$1.08 - $46.00
50D Avg
$2.73
200D Avg
$5.66
Market Cap
$78.15M
Avg Vol (3M)
$165.03K
Beta
-
Div Yield
-
FBLG Company Profile
FibroBiologics, Inc., a clinical-stage cell therapy company, develops and commercializes fibroblast-based therapies in the United States. It is developing CybroCell, for the treatment of degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for wound healing. The company is also on the early-stage research of CYTER915, which is designed to regenerate or reinvigorate production of the thymus and/or spleen; CYPS317, for the treatment of psoriasis; and TCB190 to treat certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.